US 12,441,776 B2
Oxyntomodulin peptide analog formulations
Bruce Peter Connop, Toronto (CA); Dorothy Melissa Lynn Spencer, Toronto (CA); Jagatraj Singh, Toronto (CA); Pawel Dominik Buczek, Chapel Hill, NC (US); Cale Michael Halbleib, Apex, NC (US); and Donald Edmund Kerkow, Durham, NC (US)
Assigned to EirGen Pharma Ltd., Waterford (IE)
Filed by EirGen Pharma Ltd., Waterford (IE)
Filed on Nov. 27, 2019, as Appl. No. 16/698,329.
Claims priority of provisional application 62/821,382, filed on Mar. 20, 2019.
Claims priority of provisional application 62/773,651, filed on Nov. 30, 2018.
Prior Publication US 2020/0262887 A1, Aug. 20, 2020
Int. Cl. C07K 14/605 (2006.01); A61J 1/05 (2006.01); A61K 9/00 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/60 (2017.01); A61P 3/10 (2006.01); C07K 1/02 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/605 (2013.01) [A61J 1/05 (2013.01); A61K 9/0019 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61K 47/60 (2017.08); A61P 3/10 (2018.01); C07K 1/02 (2013.01); A61K 38/00 (2013.01)] 20 Claims
 
1. A stable GLP-1 and/or Glucagon receptor agonist liquid formulation comprising a pharmaceutically effective amount of a GLP-1 and/or glucagon receptor agonist, or a pharmaceutically acceptable salt thereof, and an aqueous buffer solution, wherein the formulation has a pH value of from about 4 to about 6.5,
wherein said GLP-1 and/or Glucagon receptor agonist consists of a compound of formula 3 or 5,

OG Complex Work Unit Chemistry
wherein the aqueous buffer is selected from the group consisting of acetate buffer, citrate buffer, and histidine buffer,
wherein the liquid formulation is substantially free of cysteine or sodium chloride, and
wherein the formulation further comprises methionine and optionally comprises sorbitol.